# Health Technology Assessment Policy and Methods Review Reference Committee

## Communique – 19-20 June 2023 meeting

The Health Technology Assessment (HTA) Policy and Methods Review (Review) Reference Committee (Committee) met in person in Adelaide and by video conference on   
19-20 June 2023.

Support staff from the Review Secretariat in the Department of Health and Aged Care (Department) attended. Representatives from the Medicines Intelligence Centre of Research Excellence (MI-CRE) and from a number of HTA experts from jurisdictions around the world were invited to speak to the Committee.

### What did the Committee discuss?

### Project plan for considering options for the use of real-world data and real‑world evidence to support HTA decision making

The Committee received a briefing on the project plan prepared by MI-CRE to analyse options for optimising the use of real-world data and the production of real-world evidence to support HTA decision making. The Committee supported the project plan, noting agreement with MI-CRE representatives that there needs to be clarity on what uses and benefits are being sought from real-world data and evidence.

**Analysis of Australia market authorisation, funding and assessment pathways and timelines**

The Committee considered a detailed data collection and analysis of actual processes to gain market authorisation and funding as well as timeframes for each of the steps and relevant recent examples of technologies that have been funded or subsidised in Australia in 2021 and 2022. Further analysis was requested to continue to refine that understanding of the current state.

**Briefings from international leaders in HTA from various jurisdictions**

The Committee held discussions with the following leaders from various jurisdictions:

* Dr Nicole Mittmann – Chief Scientist and Vice-President, Scientific Evidence, Methodologies and Resources, Canadian Agency for Drug and Technologies in Health (Canada)
* Floriane Pelon – Director of Evaluation and Access to Innovation, Haute Autorité de Santé (France)
* Judith Fernandez – Deputy Director of International Activities and HTA Department, Haute Autorité de Santé (France)
* Professor Wim Goettsch – Professor of HTA of Pharmaceuticals, Utrecht University and current board member of HTAi (Netherlands)
* Professor Adrian Towse – Director Emeritus, of the Office of Health Economics (United Kingdom (UK))
* Dr Chris Henshall - independent consultant on health, research and innovation policy, Honorary Professor in the Health Economics Research Group at Brunel University and founding President of HTA international society (HTAi) (UK)
* Meindert Boysen - Head of International Affairs, National Institute for Health and Care Excellence (NICE) (UK)
* Dr Joshua Sharfstein - Vice Dean for Public Health Practice and Community Engagement, Professor of the Practice in Health Policy and Management, Johns Hopkins University (USA)
* Dr Sean Tunis – Principal of Rubix Health and Founder of the Centre for Medical Technology Policy (USA)
* Dr Hong Ju – Senior Principal Lead Specialist and Deputy Director, Agency of Care Effectiveness (Singapore)
* Associate Professor Kwong Ng – Chief HTA Officer, Agency of Care Effectiveness (Singapore).

These discussions provided the Committee with valuable insights into features, strengths and challenges in the application of HTA in different jurisdictions. This prompted discussion on the applicability of these features, strengths and challenges in the Australian context. Further engagement will likely occur with various of these jurisdictions.

**Other**

The Committee discussed various representations and engagements that Reference Committee members had had with stakeholders over the preceding month, sharing relevant insights with the broader Committee.